BOSTON SCIENTIFIC CORP's ticker is BSX and the CUSIP is 101137107. A total of 856 filers reported holding BOSTON SCIENTIFIC CORP in Q2 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.3%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Newport Trust Company, LLC | 7,401,817 | $275,866,000 | 0.89% |
| Wealth Advisors of Tampa Bay, LLC | 73,956 | $2,756,000 | 0.85% |
| Glenview Capital Management | 895,396 | $33,371,000 | 0.84% |
| Impax Asset Management Group plc | 4,488,665 | $167,293,000 | 0.82% |
| Holocene Advisors, LP | 3,581,668 | $133,489,000 | 0.81% |
| MARSHALL WACE, LLP | 10,479,137 | $390,558,000 | 0.80% |
| BRADLEY FOSTER & SARGENT INC/CT | 830,695 | $30,960,000 | 0.80% |
| Phraction Management LLC | 32,205 | $1,200,000 | 0.79% |
| Ulland Investment Advisors, LLC | 20,639 | $769,000 | 0.79% |
| NS Partners Ltd | 344,710 | $12,847,000 | 0.78% |
| Gould Capital, LLC | 24,328 | $907,000 | 0.73% |
| KBC Group NV | 3,713,369 | $138,397,000 | 0.70% |
| Ninety One UK Ltd | 6,227,082 | $232,083,000 | 0.69% |
| ASSOCIATED BANC-CORP | 418,819 | $15,610,000 | 0.68% |
| ROTHSCHILD & CO ASSET MANAGEMENT US INC. | 1,193,443 | $44,479,000 | 0.68% |
| Cinctive Capital Management LP | 434,861 | $16,207,000 | 0.68% |
| Midwest Professional Planners, LTD. | 31,992 | $1,192,000 | 0.67% |
| JANUS HENDERSON GROUP PLC | 26,045,094 | $970,705,000 | 0.67% |
| VOYA INVESTMENT MANAGEMENT LLC | 7,000,585 | $260,912,000 | 0.66% |
| LAZARD ASSET MANAGEMENT LLC | 12,653,052 | $471,578,000 | 0.64% |
About BOSTON SCIENTIFIC CORP
Boston Scientific Corp is a leading medical device company that specializes in developing innovative medical technologies. The company has a strong presence in the global market and is known for its high-quality products and services. Boston Scientific Corp has a diverse portfolio of products that cater to a wide range of medical needs, including cardiovascular, urology, and endoscopy.
The company has a strong leadership team, with Michael F. Mahoney serving as the CEO and Chairman of the Board. Under his leadership, Boston Scientific Corp has continued to grow and expand its operations. The company has a strong focus on research and development, with a significant portion of its revenue being invested in this area.
Boston Scientific Corp has also been actively involved in mergers and acquisitions, which has helped the company to expand its product portfolio and enter new markets. In 2018, the company acquired NxThera, a medical device company that specializes in treating prostate conditions. This acquisition has helped Boston Scientific Corp to strengthen its position in the urology market.
Overall, Boston Scientific Corp is a strong and reliable company that is well-positioned for future growth. With a strong leadership team, a diverse portfolio of products, and a focus on research and development, the company is poised to continue its success in the global medical device market.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BOSTON SCIENTIFIC CORP's shareholders in Q2 2022. To view BOSTON SCIENTIFIC CORP's shareholder history, click here.